{"id":"placebo-every-2-weeks","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo is administered in randomized controlled trials to establish a baseline for comparison against active drug treatments. Any observed effects are attributed to natural disease progression, regression to the mean, or the placebo effect (psychological/expectation-driven response). In Phase 3 trials, placebo serves as the comparator arm to demonstrate that the investigational drug provides clinically meaningful benefit beyond placebo response.","oneSentence":"Placebo has no active pharmacological mechanism; it is an inert substance used as a control in clinical trials.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:26:56.306Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT04199104","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-05","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":511},{"nctId":"NCT06196879","phase":"PHASE2","title":"A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)","status":"COMPLETED","sponsor":"Upstream Bio Inc.","startDate":"2024-02-27","conditions":"Severe Asthma","enrollment":479},{"nctId":"NCT05531565","phase":"PHASE2, PHASE3","title":"A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus","status":"RECRUITING","sponsor":"Biogen","startDate":"2022-09-13","conditions":"Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus","enrollment":450},{"nctId":"NCT06727552","phase":"PHASE2","title":"A Study of Barzolvolimab in Patients With Atopic Dermatitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celldex Therapeutics","startDate":"2024-12-18","conditions":"Atopic Dermatitis","enrollment":131},{"nctId":"NCT06858579","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)","status":"RECRUITING","sponsor":"Dianthus Therapeutics","startDate":"2025-02-10","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy","enrollment":480},{"nctId":"NCT06616974","phase":"PHASE2","title":"A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)","status":"RECRUITING","sponsor":"Tectonic Therapeutic","startDate":"2024-09-04","conditions":"Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction","enrollment":180},{"nctId":"NCT06132256","phase":"PHASE2","title":"MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Syndax Pharmaceuticals","startDate":"2023-12-11","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":145},{"nctId":"NCT05287113","phase":"PHASE2","title":"Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Biosciences International Sàrl","startDate":"2022-11-14","conditions":"Head and Neck Cancer","enrollment":176},{"nctId":"NCT02194738","phase":"NA","title":"Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-09-26","conditions":"Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8","enrollment":8300},{"nctId":"NCT06603077","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa","status":"ACTIVE_NOT_RECRUITING","sponsor":"Avalo Therapeutics, Inc.","startDate":"2024-09-16","conditions":"Hidradenitis Suppurativa","enrollment":250},{"nctId":"NCT07284316","phase":"PHASE2, PHASE3","title":"Effect of a Multidomain Intervention Plus Turmeric on the Prevention of Cognitive Decline in People Over 55 Years of Age With Insulin Resistance.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Instituto Mexicano del Seguro Social","startDate":"2025-02-20","conditions":"Cognitive Decline, Subjective Cognitive Impairment, Insulin Resistance","enrollment":100},{"nctId":"NCT06247345","phase":"PHASE1","title":"A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01","status":"SUSPENDED","sponsor":"Alzheimer's Disease Expert Lab (ADEL), Inc.","startDate":"2024-02-06","conditions":"Alzheimer Disease","enrollment":73},{"nctId":"NCT07492446","phase":"NA","title":"Effects of Carnitine Supplementation on Exercise-Induced Muscle Damage: A Randomized Controlled Trial","status":"COMPLETED","sponsor":"Istanbul Sabahattin Zaim University","startDate":"2025-05-09","conditions":"Recovery Methods, Exercise and Recovery, Exercise Fatigue","enrollment":30},{"nctId":"NCT07485764","phase":"PHASE4","title":"Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2026-06","conditions":"Psoriasis, Plaque Psoriasis, Moderate-to-severe Plaque Psoriasis","enrollment":186},{"nctId":"NCT06578728","phase":"PHASE4","title":"Local Methotrexate Injections for the Treatment of Nail Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2025-09-10","conditions":"Nail Psoriasis","enrollment":1},{"nctId":"NCT07221474","phase":"PHASE2","title":"A Study of V940/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-12-12","conditions":"Squamous Non-small Cell Lung Cancer","enrollment":180},{"nctId":"NCT06339008","phase":"PHASE3","title":"A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-04-26","conditions":"Perennial Allergic Rhinitis (PAR)","enrollment":450},{"nctId":"NCT06676319","phase":"PHASE2","title":"Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-11-07","conditions":"Asthma","enrollment":1147},{"nctId":"NCT06466135","phase":"PHASE2","title":"Study of WAL0921 in Patients With Glomerular Kidney Diseases","status":"RECRUITING","sponsor":"Walden Biosciences","startDate":"2024-07-02","conditions":"Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis, Minimal Change Disease","enrollment":96},{"nctId":"NCT06338995","phase":"PHASE3","title":"A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-04-29","conditions":"Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)","enrollment":510},{"nctId":"NCT06623422","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-10-21","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":680},{"nctId":"NCT07404891","phase":"NA","title":"Clinical Trial on the Efficacy and Safety of ALT001 in Osteoarthritis","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2026-03-18","conditions":"Osteoarthritis","enrollment":30},{"nctId":"NCT04003636","phase":"PHASE3","title":"Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-09-24","conditions":"Biliary Tract Carcinoma","enrollment":1069},{"nctId":"NCT04520607","phase":"PHASE3","title":"A Long-Term Safety and Efficacy Study of Lorecivivint in Subjects With Osteoarthritis of the Knee","status":"TERMINATED","sponsor":"Biosplice Therapeutics, Inc.","startDate":"2020-08-25","conditions":"Osteoarthritis, Knee","enrollment":276},{"nctId":"NCT05075824","phase":"PHASE2","title":"A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-03-09","conditions":"Sickle Cell Disease","enrollment":90},{"nctId":"NCT06788990","phase":"PHASE2, PHASE3","title":"FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC","status":"RECRUITING","sponsor":"Bicara Therapeutics","startDate":"2025-01-28","conditions":"Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma","enrollment":650},{"nctId":"NCT06186492","phase":"PHASE1","title":"A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT Expression (RestorAATion-1)","status":"COMPLETED","sponsor":"Wave Life Sciences Ltd.","startDate":"2023-11-14","conditions":"Alpha-1 Antitrypsin Deficiency (AATD)","enrollment":47},{"nctId":"NCT06311682","phase":"PHASE3","title":"A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis","status":"RECRUITING","sponsor":"LEO Pharma","startDate":"2024-06-10","conditions":"Atopic Dermatitis","enrollment":195},{"nctId":"NCT05352919","phase":"PHASE3","title":"An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus","status":"ENROLLING_BY_INVITATION","sponsor":"Biogen","startDate":"2022-06-10","conditions":"Systemic Lupus Erythematosus (SLE)","enrollment":864},{"nctId":"NCT05263206","phase":"PHASE3","title":"Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)","status":"RECRUITING","sponsor":"Sanofi","startDate":"2022-02-15","conditions":"Pruritus","enrollment":284},{"nctId":"NCT06468228","phase":"PHASE3","title":"A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-06-27","conditions":"Hidradenitis Suppurativa","enrollment":1280},{"nctId":"NCT04763343","phase":"PHASE3","title":"Ketamine Treatment of Youth Suicide Attempters","status":"RECRUITING","sponsor":"Tatiana Falcone, MD","startDate":"2022-06-27","conditions":"Suicide, Attempted","enrollment":60},{"nctId":"NCT05097287","phase":"PHASE4","title":"Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma","status":"RECRUITING","sponsor":"Sanofi","startDate":"2021-12-16","conditions":"Asthma","enrollment":1324},{"nctId":"NCT04543591","phase":"PHASE3","title":"Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2020-12-10","conditions":"Thrombotic Microangiopathy","enrollment":148},{"nctId":"NCT04191096","phase":"PHASE3","title":"Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-12","conditions":"Metastatic Hormone-Sensitive Prostate Cancer","enrollment":1251},{"nctId":"NCT05029141","phase":"PHASE2","title":"New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2021-09-01","conditions":"Acute Myeloid Leukemia, Refractory Acute Leukemia, Relapsed Adult AML","enrollment":21},{"nctId":"NCT04944836","phase":"PHASE2","title":"Sex Hormone Supplementation and Rotator Cuff Repair: A Preliminary Randomized Trial","status":"RECRUITING","sponsor":"University of Utah","startDate":"2023-03-09","conditions":"Rotator Cuff Tears","enrollment":58},{"nctId":"NCT06750289","phase":"PHASE3","title":"Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-28","conditions":"Eosinophilic Asthma","enrollment":400},{"nctId":"NCT06732388","phase":"PHASE2","title":"Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-02-16","conditions":"Barrett Esophagus, Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8","enrollment":64},{"nctId":"NCT03844412","phase":"PHASE2","title":"Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments","status":"COMPLETED","sponsor":"Duke University","startDate":"2019-11-04","conditions":"Vestibulodynia, Temporomandibular Disorder, Fibromyalgia Syndrome","enrollment":209},{"nctId":"NCT02720094","phase":"PHASE2, PHASE3","title":"Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-12-19","conditions":"HIV Infections","enrollment":4570},{"nctId":"NCT07161999","phase":"PHASE2","title":"Study of COYA 302 for the Treatment of ALS","status":"RECRUITING","sponsor":"Coya Therapeutics","startDate":"2025-10-01","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":120},{"nctId":"NCT06611111","phase":"EARLY_PHASE1","title":"Ceftriaxone Pulse Dose for Post-Treatment Lyme Disease","status":"RECRUITING","sponsor":"State University of New York - Upstate Medical University","startDate":"2025-02-03","conditions":"Post-Treatment Lyme Disease","enrollment":44},{"nctId":"NCT07257029","phase":"PHASE2","title":"Topical Ketotifen 0.25% for Secondary Vestibulodynia","status":"RECRUITING","sponsor":"Center for Vulvovaginal Disorders","startDate":"2026-01-02","conditions":"Provoked Vestibulodynia, Secondary Provoked Vestibulodynia, Vulvodynia","enrollment":54},{"nctId":"NCT04639050","phase":"PHASE1, PHASE2","title":"Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-03-15","conditions":"Alzheimers Disease","enrollment":241},{"nctId":"NCT06726265","phase":"PHASE3","title":"Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Immutep S.A.S.","startDate":"2025-03-21","conditions":"Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)","enrollment":756},{"nctId":"NCT07024641","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection","status":"RECRUITING","sponsor":"GigaGen, Inc.","startDate":"2024-11-13","conditions":"Hepatitis B Virus Infection","enrollment":48},{"nctId":"NCT07281937","phase":"PHASE2","title":"A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities","status":"ACTIVE_NOT_RECRUITING","sponsor":"Verdiva Bio Dev Limited","startDate":"2025-11-25","conditions":"Obesity, Overweight","enrollment":206},{"nctId":"NCT04870203","phase":"PHASE3","title":"Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Bordeaux","startDate":"2021-07-15","conditions":"Rheumatoid Arthritis","enrollment":160},{"nctId":"NCT05842330","phase":"PHASE3","title":"Benefits of ADHD Treatment in Detained People","status":"RECRUITING","sponsor":"Stéphanie Baggio","startDate":"2024-01-01","conditions":"ADHD","enrollment":150},{"nctId":"NCT06950385","phase":"PHASE3","title":"Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis","status":"RECRUITING","sponsor":"Rapamycin Holdings Inc.","startDate":"2025-07-18","conditions":"Familial Adenomatous Polyposis (FAP)","enrollment":168},{"nctId":"NCT06113328","phase":"PHASE2","title":"A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-11-27","conditions":"Non-segmental Vitiligo","enrollment":169},{"nctId":"NCT03100149","phase":"PHASE2","title":"A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2017-06-27","conditions":"Parkinson's Disease","enrollment":316},{"nctId":"NCT04404283","phase":"PHASE3","title":"Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2020-08-20","conditions":"Diffuse Large B-cell Lymphoma","enrollment":238},{"nctId":"NCT03537742","phase":"PHASE2","title":"Cardiac Allograft Vasculopathy Inhibition With Alirocumab","status":"COMPLETED","sponsor":"Stanford University","startDate":"2019-05-13","conditions":"Vasculopathy","enrollment":114},{"nctId":"NCT07061574","phase":"PHASE1, PHASE2","title":"A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-03-30","conditions":"Type 1 Diabetes, New Onset","enrollment":120},{"nctId":"NCT04119050","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-08-15","conditions":"Warm Autoimmune Hemolytic Anemia","enrollment":118},{"nctId":"NCT01631617","phase":"PHASE2","title":"Effects of Treatments on Atopic Dermatitis","status":"RECRUITING","sponsor":"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","startDate":"2012-09-18","conditions":"Eczema, Dermatitis, Skin Diseases, Genetic","enrollment":130},{"nctId":"NCT04150068","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2019-11-21","conditions":"HIV-1-infection","enrollment":72},{"nctId":"NCT05115110","phase":"PHASE2, PHASE3","title":"A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-06-02","conditions":"Spinal Muscular Atrophy (SMA)","enrollment":259},{"nctId":"NCT05271409","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-08-30","conditions":"Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)","enrollment":152},{"nctId":"NCT05523323","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-10-30","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":112},{"nctId":"NCT06736990","phase":"PHASE2","title":"A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis","status":"RECRUITING","sponsor":"Calluna Pharma AS","startDate":"2025-06-20","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":150},{"nctId":"NCT05664477","phase":"PHASE2","title":"PhytoSERM to Prevent Menopause Associated Decline in Brain Metabolism and Cognition","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roberta Brinton","startDate":"2024-01-10","conditions":"Menopause, Cognitive Change, Brain Disorder, Metabolic","enrollment":100},{"nctId":"NCT05327114","phase":"PHASE2, PHASE3","title":"Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-09-23","conditions":"Polyradiculoneuropathy, Chronic Inflammatory Demyelinating","enrollment":201},{"nctId":"NCT04468659","phase":"PHASE3","title":"AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eisai Inc.","startDate":"2020-07-14","conditions":"Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease","enrollment":1400},{"nctId":"NCT04590963","phase":"PHASE3","title":"Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-10-02","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":370},{"nctId":"NCT06996652","phase":"PHASE2","title":"An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)","status":"NOT_YET_RECRUITING","sponsor":"Yale University","startDate":"2026-04","conditions":"REM Sleep Behavior Disorder","enrollment":108},{"nctId":"NCT07033494","phase":"PHASE2","title":"A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-16","conditions":"Early Alzheimer's Disease","enrollment":340},{"nctId":"NCT05379634","phase":"PHASE2","title":"A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-07-05","conditions":"Myositis","enrollment":36},{"nctId":"NCT06322628","phase":"PHASE2","title":"A Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of VSA006 in Chinese NASH Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Visirna Therapeutics HK Limited","startDate":"2024-04-22","conditions":"Nash","enrollment":48},{"nctId":"NCT03451851","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-07-11","conditions":"Psoriasis","enrollment":120},{"nctId":"NCT06079281","phase":"PHASE3","title":"Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2024-01-03","conditions":"Hypophosphatasia","enrollment":124},{"nctId":"NCT07137585","phase":"PHASE1","title":"A Study to Evaluate the Effect of RO7204239 on Insulin Sensitivity and Muscle Composition in Participants With Type 2 Diabetes Mellitus (T2DM) and Overweight or Obesity","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-09-30","conditions":"Type 2 Diabetes Mellitus, Obesity, Overweight","enrollment":30},{"nctId":"NCT04033445","phase":"PHASE2, PHASE3","title":"A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-09-26","conditions":"Ulcerative Colitis","enrollment":1064},{"nctId":"NCT05649137","phase":"PHASE3","title":"A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-01-04","conditions":"Obesity, Diabetes Mellitus, Type 2","enrollment":512},{"nctId":"NCT04179175","phase":"PHASE3","title":"Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2020-03-18","conditions":"Hidradenitis Suppurativa","enrollment":703},{"nctId":"NCT06901531","phase":"PHASE3","title":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2025-05-22","conditions":"Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer","enrollment":500},{"nctId":"NCT05622708","phase":"PHASE4","title":"A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-03-28","conditions":"Non-radiographic Axial Spondyloarthritis","enrollment":240},{"nctId":"NCT06979375","phase":"PHASE2","title":"A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-06-30","conditions":"Heart Failure","enrollment":200},{"nctId":"NCT06641089","phase":"PHASE3","title":"Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response","status":"RECRUITING","sponsor":"MoonLake Immunotherapeutics AG","startDate":"2024-10-15","conditions":"Arthritis, Psoriatic","enrollment":600},{"nctId":"NCT06868212","phase":"PHASE3","title":"A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-07-11","conditions":"Chronic Spontaneous Urticaria (CSU)","enrollment":400},{"nctId":"NCT06979362","phase":"PHASE2","title":"A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-06-27","conditions":"Heart Failure","enrollment":200},{"nctId":"NCT07462130","phase":"PHASE1, PHASE2","title":"An Efficacy and Safety Study of NTB003 in Participants With Thyroid Eye Disease (TED)","status":"NOT_YET_RECRUITING","sponsor":"Nanjing Chia-tai Tianqing Pharmaceutical","startDate":"2026-03-01","conditions":"Thyroid Eye Disease","enrollment":74},{"nctId":"NCT06443918","phase":"NA","title":"A Just-in-Time Adaptive Intervention for Child and Family Mental Health","status":"COMPLETED","sponsor":"Colliga Apps Corp.","startDate":"2024-05-20","conditions":"Mental Health and Well-being, Family Functioning","enrollment":347},{"nctId":"NCT04205812","phase":"PHASE3","title":"Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2020-09-11","conditions":"Metastatic Squamous Non-Small Cell Lung Cancer, Metastatic Nonsquamous Non-Small Cell Lung Cancer","enrollment":583},{"nctId":"NCT06349473","phase":"PHASE1","title":"A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)","status":"RECRUITING","sponsor":"Equilibra Bioscience LLC","startDate":"2024-05-10","conditions":"Healthy Participants, Hemophilia A, Hemophilia B","enrollment":31},{"nctId":"NCT07038824","phase":"PHASE1, PHASE2","title":"A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45","status":"RECRUITING","sponsor":"Entrada Therapeutics, Inc.","startDate":"2025-08-30","conditions":"Duchenne Muscular Dystrophy (DMD)","enrollment":24},{"nctId":"NCT06144710","phase":"PHASE1","title":"SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hangzhou Sumgen Biotech Co., Ltd.","startDate":"2023-11-10","conditions":"Systemic Lupus Erythematosus (SLE)","enrollment":48},{"nctId":"NCT05116189","phase":"PHASE3","title":"Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-12-13","conditions":"Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms","enrollment":643},{"nctId":"NCT06961006","phase":"PHASE2","title":"A Clinical Study of V940 and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-05-29","conditions":"Malignant Melanoma","enrollment":160},{"nctId":"NCT07037862","phase":"PHASE1, PHASE2","title":"A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44","status":"RECRUITING","sponsor":"Entrada Therapeutics, Inc.","startDate":"2025-06-30","conditions":"Duchenne Muscular Dystrophy (DMD)","enrollment":24},{"nctId":"NCT04381897","phase":"PHASE2","title":"Use of N-Acetylcysteine in the Treatment of Repetitive and Self-Injurious Behaviors in Cornelia de Lange Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-08-01","conditions":"Cornelia de Lange Syndrome","enrollment":10},{"nctId":"NCT05503264","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-09-27","conditions":"NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis","enrollment":152},{"nctId":"NCT04206553","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-10-28","conditions":"Bullous Pemphigoid","enrollment":106},{"nctId":"NCT06295458","phase":"NA","title":"Gamma Sensory Flicker for Parkinson's Disease Patients With Freezing of Gait","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2024-07-08","conditions":"Gait Disorders, Neurologic, Parkinson Disease","enrollment":24},{"nctId":"NCT02362594","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-07-16","conditions":"Melanoma","enrollment":1019},{"nctId":"NCT07226050","phase":"PHASE2","title":"CLF065 for Chronic Pouchitis","status":"RECRUITING","sponsor":"Calibr, a division of Scripps Research","startDate":"2026-03-05","conditions":"Pouchitis","enrollment":20},{"nctId":"NCT07447986","phase":"PHASE2","title":"To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus","status":"NOT_YET_RECRUITING","sponsor":"Hangzhou Sumgen Biotech Co., Ltd.","startDate":"2026-03-15","conditions":"Systemic Lupus Erythematosus (SLE)","enrollment":120},{"nctId":"NCT05726292","phase":"PHASE2","title":"A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-01-06","conditions":"Prostate Cancer, Prostate Adenocarcinoma","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1410,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo every 2 weeks","genericName":"Placebo every 2 weeks","companyName":"Eli Lilly and Company","companyId":"eli-lilly","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}